Obstetrics & gynecology science

Korean Society of Obstetrics and Gynecology (대한산부인과학회)
권호 표지

Recent Advances in the Management of Polycystic Ovary Syndrome

다낭성난소증후군 치료의 최신지견

Kim, Chung-Hoon
김정훈

  • Published : 20050800
⟨ Previous Next ⟩

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, and the most frequent cause of anovulatory infertility with high circulating levels of luteinizing hormone (LH), chronic hyperandrogenemia, and insulin resistance. PCOS is a heterogeneous disorder with a broad spectrum of clinical manifestations. PCOS patients with chronic anovulation or hyperandrogenism or insulin resistance develop clinical problems. Therefore, appropriate tailored therapeutic management is essential for them, and a multidisciplinary approach is frequently needed. The aim of treatment in PCOS is for (1) improvement of endocrine-metabolic derangement and prevention of consequences of metabolic sequelae (cardiovascular disease, DM), (2) protection of endometrium against the effects of unopposed estrogen, (3) symptomatic treatment such as control of DUB, (4) cosmetic effects such as improvement of acne, hirsutism and achievement of normal body weight, (5) ovulation induction to achieve pregnancy in infertile PCOS women. Therefore, we should try to (1) improve hyperinsulinemia and/or avoid the effects of hyperinsulinemia, (2) reduce the production & circulating levels of androgens, (3) supplement progestins periodically, and (4) induce the ovulation in women desiring pregnancy. The specific treatment depends on a patient’s goals and characteristics. Weight reduction and therapies with insulin sensitizing drugs should be considered as a primary treatment in obese PCOS women irrespective of patient's goals. In PCOS patients desiring pregnancy, appropriate algorithm for ovulation induction should be considered before starting the ovulation induction. Once ovulation has been documented for a particular therapy, patients should be mentally prepared to continue with that regimen for at least three cycles. The management plan for patients should be reviewed at least once every 3 cycles and more frequently if complications or abnormal ovarian responses are present. A better understanding of the pathogenesis of PCOS leads to novel therapies. We are actually entering a new era in management of PCOS women. Important benefits will be derived from the long-term aggressive preventive health care attitude in PCOS women with obesity, insulin resistance and/or chronic anovulation.

Keywords

References

  1. Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-91
  2. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50: 197- 212
  3. Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol 1989; 31: 87-120 https://doi.org/10.1111/j.1365-2265.1989.tb00457.x
  4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
  5. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2031-6 https://doi.org/10.1210/jc.2002-021499
  6. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75: 53-8 https://doi.org/10.1016/S0015-0282(00)01662-9
  7. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-9 https://doi.org/10.1210/jc.84.1.165
  8. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001; 75: 177-84 https://doi.org/10.1016/S0020-7292(01)00477-5
  9. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996; 66(6): 942-7
  10. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73(7): 460-8 https://doi.org/10.1016/0002-9149(94)90676-9
  11. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105-11 https://doi.org/10.1111/j.1365-2265.1992.tb02909.x
  12. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-4 https://doi.org/10.1210/jc.84.4.1470
  13. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 1876-80
  14. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: 392-5 https://doi.org/10.1016/S0029-7844(97)00296-2
  15. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524-30 https://doi.org/10.1210/jc.82.2.524
  16. Nestler JE, Stovall D, Akhter N, Iuomo MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209-15 https://doi.org/10.1016/S0015-0282(01)02963-6
  17. Nestler JE, Strauss JF. Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocr Metab Clin North Am 1991; 20: 807-23
  18. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19: 2474-83 https://doi.org/10.1093/humrep/deh440
  19. DeLeo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: 282-5 https://doi.org/10.1016/S0015-0282(99)00208-3
  20. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001; 76: 517-24 https://doi.org/10.1016/S0015-0282(01)01975-6
  21. Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16: 241-5 https://doi.org/10.1007/BF01221950
  22. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 2005; 83(5): 1575-8 https://doi.org/10.1016/j.fertnstert.2004.11.051
  23. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-306 https://doi.org/10.1210/jc.81.9.3299
  24. Mitwally MF, Kuscu NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999; 14: 2700-3 https://doi.org/10.1093/humrep/14.11.2700
  25. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebocontrolled trial. J Clin Endocrinol Metab 2001; 86(4): 1626- 32 https://doi.org/10.1210/jc.86.4.1626
  26. Tafuri SR. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 1996; 137: 4706-12 https://doi.org/10.1210/en.137.11.4706
  27. Kim CH, Hong SH, Nah HY, Kim SH, Chae HD, Kang BM. Effects of rosiglitazone on ovarian stromal blood flow, ovarian stimulation and outcome in patients with polycystic ovary syndrome undergoing in vitro fertilization. Hum Reprod 2003; 18(S1): 172 https://doi.org/10.1093/humrep/deg008
  28. Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81(3): 624-9 https://doi.org/10.1016/j.fertnstert.2003.08.024
  29. 이향아,김정훈,최정원,박선정,이수정,최은선 등. 다낭성난소 증후군 환자에서 pioglitazone이 인슐린 민감도, 난소 기능, 난소기질 내 혈류에 미치는 영향. 대한불임학회지 2005; 32: 155-64
  30. Fulghesu AM, Clampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-Acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 2002; 77(6): 1128-35 https://doi.org/10.1016/S0015-0282(02)03133-3
  31. Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril 2005; 83: 367-70 https://doi.org/10.1016/j.fertnstert.2004.07.960
  32. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Alan G. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314-20 https://doi.org/10.1056/NEJM199904293401703
  33. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001; 75(2): 305-9 https://doi.org/10.1016/S0015-0282(00)01705-2
  34. Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 85(3): 289-91 https://doi.org/10.1016/j.ijgo.2003.11.010
  35. 김정훈,채희동,강은희,추형식,강병문,장윤석. 다낭성난소증 후군 환자들에서 배란 유도시 성장억제 호르몬 유사체가 난소반응에 미치는 영향. 대한산부회지 1999; 42; 496-503
  36. 이종표,김흥권,신혜진,강은희,채희동,김정훈 등. 다낭성난소 증후군 환자들에서 배란유도시 성장억제호르몬 유사체의 전처치가 난소 반응에 미치는 영향. 대한산부회지 2000; 43: 423-30
  37. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotrophin releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79: 873-90 https://doi.org/10.1016/S0015-0282(02)04920-8
  38. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? Hum Reprod 1999; 14: 2959-62 https://doi.org/10.1093/humrep/14.12.2959
  39. Bracero N, Jurema M, Vlahos N, Kolp L, Garcia J. Polycystic ovarian syndrome (PCOS) patients have a favorable response to ganirelix acetate during controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF)-embryo transfer (ET). Fertil Steril 2002; 78(suppl 3): S149-50
  40. Elkind-Hirsch KE, Webster BW, Brown C, Vernon MW. Concurrent Antagon and Follistim therapy for ovulation induction in women with polycystic ovary syndrome (PCOS). Fertil Steril 2003; 79: 603-7 https://doi.org/10.1016/S0015-0282(02)04696-4
  41. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre- treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004; 19: 1993-2000 https://doi.org/10.1093/humrep/deh375
  42. 최정원,김정훈,이향아,홍석호,나희영,이영진 등. 체외수 정시술을 받는 다낭성난소증후군 환자들에서 GnRH antagonist 를 이용한 과배란유도의 효용성. 대한산부회지 2005; 48(3): 716-25
  43. Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985; 23: 341-7 https://doi.org/10.1111/j.1365-2265.1985.tb01090.x
  44. Heiner JS, Greendale GA, Kawakami AK, Lapolt PS, Fisher M, Young D, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J Clin Endocrinol Metab 1995; 80: 3412-8 https://doi.org/10.1210/jc.80.12.3412
  45. Azziz R, Ochoa TM, Bradley EL, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab 1995; 80: 3406-11 https://doi.org/10.1210/jc.80.12.3406